This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DARA BioSciences Is Selected By MDB Capital Group As A 2011 "Best & Brightest-Company To Watch"

RALEIGH, N.C., Feb. 23, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a Raleigh, North Carolina biopharmaceutical drug development company, has been selected by MDB Capital Group as a 2011 "Best & Brightest" company and a "Company to Watch."

"Being chosen as a 'Best & Brightest' (BB) Company is recognition of the extraordinary work we are doing in developing new medicines to treat some of the most life-threatening diseases and debilitating chronic conditions, which we hope will result in a healthier tomorrow. Everyone at DARA BioSciences is honored by our company's selection," said Richard A. Franco, CEO/President of DARA BioSciences. Prior to co-founding DARA BioSciences in 2003, Mr. Franco was co-founder of LipoScience, Inc., senior strategist for a multi-national pharmaceutical giant, and an entrepreneur.

Christopher Marlett, CEO of MDB Capital Group, commended the DARA BioSciences management team by saying, "The Company's imbedded IP value and demonstrated innovation places it in the top 10% of the approximately 1500 technology companies trading below $500MM in market value as ranked by our proprietary IP intelligence database called PatentVest.  Our research has shown that this elite group of companies demonstrating above average PatentVest metrics, such as PatentVest Tech Score and the compound annual growth rate (CAGR) of patent applications, has significantly outperformed their publicly traded peers.  In addition, companies in this group have demonstrated higher margins and more sustained growth."

A link to the PatentVest report can be found at MDB Capital Group's website at www.mdb.com

DARA currently has two drugs in clinical development that have the potential to help people with cancer and diabetes. KRN5500 has successfully completed a Phase 2 study for the treatment of neuropathic pain and is in partnership with the National Cancer Institute to study the treatment and prevention of chemotherapy induced peripheral neuropathy in cancer patients. DB959 has completed its first Phase I clinical study and plans to start a second in Q1 2011 for the treatment of type 2 diabetes potentially without having the side effects from other medicines now being used. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs